AMERI_1170x120_11-6-20

Ending the pandemic will require innovation and access

Ending the pandemic will require innovation and access

Long after the sun goes down, the work of America’s biopharmaceutical companies continues deep into the night. Researchers and scientists labor around the clock, developing new ways to diagnose, treat and cure COVID-19. While they do, so many of the people they’re working to help stare at the ceiling and wonder how they will afford

Pharmacy Outlook: Stephen Ubl, PhRMA

Pharmacy Outlook: Stephen Ubl, PhRMA

Not so long ago, people diagnosed with hepatitis C faced a lifetime of serious complications. The virus would progress slowly, and over time, could cause extensive liver damage. But that’s not the case anymore for the vast majority of patients with the disease. Thanks to medical research and innovation over the past 25 years, patients

Making health care work better for patients

Making health care work better for patients

Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. Pharmacists are medication experts. Every day, they get to see the remarkable difference innovative treatments can make in their customers’ lives. But like America’s biopharmaceutical companies, they also know those innovative medicines aren’t nearly as meaningful if they are too

Time to start sharing the Rx savings with patients

Time to start sharing the Rx savings with patients

Every day at America’s community pharmacies, patients pay a bigger and bigger share of the cost for their prescription medications. But two new studies have revealed one of the puzzling reasons why — and how market-based solutions could help ease the strain on America’s patients. Like any complex U.S. industry, the biopharmaceutical sector relies on

Good news in Rx: Treatment options keep growing

Good news in Rx: Treatment options keep growing

When chain drug store customers are waiting in line at the pharmacy, odds are they have at least one thing on their mind: relief for their disease or condition. The good news is that at the start of 2017, America’s chain drug store customers will see more available treatment options than at any other time